Transcriptional profiling of proliferative skeletal muscle mononucleated cells coupled with broadband electrical cytometry towards diagnosis of myalgic encephalomyelitis/chronicfatiguesyndrome
Project Number1R21NS139044-01
Contact PI/Project LeaderCHENG, XUANHONG
Awardee OrganizationLEHIGH UNIVERSITY
Description
Abstract Text
Transcriptional profiling of proliferative skeletal muscle mononucleated cells coupled with broadband
electrical cytometry towards diagnosis of myalgic encephalomyelitis/chronicfatiguesyndrome
PROJECT SUMMARY / ABSTRACT
Myalgic Encephalomyelitis/ChronicFatigueSyndrome (ME/CFS) is a debilitating, acquired disease affecting up
to 2.5 million Americans. With increasing evidence that a proportion of patients with COVID-19 experience
prolonged convalescence and chronic symptoms similar to ME/CFS, it is suggested that the incidence of
ME/CFS will increase significantly. Currently, no single biomarkers or pathognomonic signs have been identified
for diagnostic measures. Instead, diagnosis is based on clinical symptoms after exclusion of other possible
etiologies known to cause fatigue, a method that does not prescribe adequate sensitivity or specificity. Since
clinical symptoms suggest that skeletal muscle is a major and consistent target of the pathology, and proliferative
skeletal mononucleated cells (SMMCs) are excellent indicators of muscle disorders, we hypothesize that
proliferative SMMCs from of ME/CFS patients are distinguishable from those of healthy individuals on the
molecular and cellular level. Proposed work will investigate gene expression, functional pathways and electrical
characteristics of single SMMCs from ME/CFS and healthy donors to identify a matrix of molecular and
biophysical markers to enable future development of diagnostics. Single-cell mRNA profiling will identify
differential gene expression describing alterations that occur in ME/CFS samples. Using differential biomarkers
identified by scRNA-seq, subpopulations of SMMCs unique to ME/CFS will be sorted to study changes in protein
expression and cell function. Furthermore, an impedance cytometer recently developed by our team will be used
to measure single cell electrical spectra, and disease-specific signatures will be identified by machine learning.
The molecular, cellular and electrical characteristics will be further correlated with each other to provide a
comprehensive understanding of the SMMC pathology in ME/CFS, an untapped subject. The proposed single-
cell transcriptome analysis of SMMCs from ME/CFS patients represents the first study of its kind and will greatly
contribute to the fundamental knowledge of the role of proliferative SMMCs in ME/CFS dysfunctions. Compared
to molecular approaches, proposed impedance cytometry captures a ‘big picture’ of the multitude of changes
contributing to abnormalities in ME/CFS SMMCs. As specific molecular markers have not been identified for
diagnostic measures, the holistic electrical characteristics of single cells offer a unique perspective of global
changes in SMMCs and hold great diagnostic potential in the future. Integration of electrical and biological studies
of SMMCs will further allow interpretation of the impedance spectra to promote sensing specificity.
Public Health Relevance Statement
PROJECT NARATIVE
Despite its prevalence, ME/CFS remains a poorly understood disease that lacks lab-based, objective diagnostic
markers. We propose to study the gene expression, function and electrical property of donor derived, proliferative
adult skeletal muscle mononucleated cells (SMMCs). The resulting electrical characteristics coupled with single
cell genetic and biological studies have a potential to identify pathology and biomarkers in these cells for future
development of ME/CFS diagnostics.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
808264444
UEI
E13MDBKHLDB5
Project Start Date
04-September-2024
Project End Date
31-August-2026
Budget Start Date
04-September-2024
Budget End Date
31-August-2026
Project Funding Information for 2024
Total Funding
$390,178
Direct Costs
$283,648
Indirect Costs
$106,530
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$390,178
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21NS139044-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21NS139044-01
Patents
No Patents information available for 1R21NS139044-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21NS139044-01
Clinical Studies
No Clinical Studies information available for 1R21NS139044-01
News and More
Related News Releases
No news release information available for 1R21NS139044-01
History
No Historical information available for 1R21NS139044-01
Similar Projects
No Similar Projects information available for 1R21NS139044-01